Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

MLA

James S, McCarthy, et al. “Safety, Tolerability, Pharmacokinetics, and Activity of the Novel Long-Acting Antimalarial DSM265: A Two-Part First-in-Human Phase 1a/1b Randomised Study.” The Lancet. Infectious Diseases, vol. 17, no. 6, Jan. 2017, pp. 626–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....53a113a360d4773f742df152c454b73b&authtype=sso&custid=ns315887.

APA

James S, M., Julie, L., Thomas, R., Stephan, C., Margaret A, P., Suzanne, E., Silvana, S., Paul, G., Caroline L, N., David A, F., Louise, M., Noelle S, W., Nathalie, G., Lidiya, B., Maria, R., Kennan, M., & Jörg J, M. (2017). Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. The Lancet. Infectious Diseases, 17(6), 626–635.

Chicago

James S, McCarthy, Lotharius Julie, Rückle Thomas, Chalon Stephan, Phillips Margaret A, Elliott Suzanne, Sekuloski Silvana, et al. 2017. “Safety, Tolerability, Pharmacokinetics, and Activity of the Novel Long-Acting Antimalarial DSM265: A Two-Part First-in-Human Phase 1a/1b Randomised Study.” The Lancet. Infectious Diseases 17 (6): 626–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....53a113a360d4773f742df152c454b73b&authtype=sso&custid=ns315887.